BAB V SIMPULAN DAN SARAN
5.2 Saran
Perlu dilakukan penelitian eksperimental dengan matching sampel di awal penelitian untuk menghilangkan kemungkinan adanya faktor perancu dalam penelitian. Penilaian hambatan gerak bola mata dilakukan hanya oleh satu atau dua spesialis mata untuk menghindari subjektivitas atau dengan membandingkan foto gerak bola mata pasien setiap kunjungan. Diperlukan analisis lanjutan faktor-faktor apa saja yang dapat mempengaruhi tingkat keberhasilan pemberian kortikosteroid pada kasus paralisis nervus okular motor terisolasi akibat iskemik mikrovaskular serta ada tidaknya interaksi obat antara kortikosteroid dengan agen neuroprotektor lainnya.
64
65
Nerve Palsy as an Indicator of Neglected Systemic Disease in Nigeria:
Perspective from a Neuro-Ophthalmology Clinic. Neuroophthalmology.
2019; 43(6): 355-62.
2. Fang C, Leavitt JA, Hodge DO, Holmes JM, Mohney BG, Chen JJ. Incidence and Etiologies of Acquired Third Nerve Palsy Using a Population-Based Method. JAMA Ophthalmol. 2017; 135(1): 23-8.
3. Choi KD, Choi SY, Kim JS, Choi JH, Yang TH, Oh SY, et al. Acquired Ocular Motor Nerve Palsy in Neurology Clinics: A Prospective Multicenter Study. J Clin Neurol. 2019; 15(2): 221-7.
4. Marselina M, Kartika A. Karakteristik Klinis Pasien Dengan Paralisis Nervus Okular Motor Terisolasi di Rumah Sakit Mata Cicendo. Departemen Ilmu Kesehatan Mata Fakultas Kedokteran Universitas Padjadjaran Pusat Mata Nasional Rumah Sakit Mata Cicendo Bandung, 2017.
5. Kung NH, Van Stavern GP. Isolated ocular motor nerve palsies. Semin Neurol. 2015; 35: 539-48.
6. Khadse R, Pawar N, Padmavathy SR, Ramakrishanan MR. Clinical profile of ocular motor nerve palsies at a tertiary centre in southern India. EC Ophthalmol. 2017; 6: 89–94.
7. Tamhankar MA, Biousse V, Ying GS, Prasad S, Subramanian PS, Lee MS, et al. Isolated third, fourth, and sixth cranial nerve palsies from presumed
microvascular versus other causes: a prospective study. Ophthalmology.
2013; 120: 2264-9.
8. Chou KL, Galetta SL, Liu GT, Volpe NJ, Bennett JL, Asbury AK, et al.
Acute ocular motor mononeuropathies: prospective study of the roles of neuroimaging and clinical assessment. J Neurol Sci. 2004; 219: 35-9.
9. Pineles SL, Velez FG. Isolated Ocular Motor Nerve Palsies. J Binocul Vis Ocul Motil. 2018; 68(3): 70-7.
10. Nazerian P, Vanni S, Tarocchi C, Portaccio E, Vannucci N, Para O, et al.
Causes of diplopia in the emergency department: diagnostic accuracy of clinical assessment and of head computed tomography. Eur J Emerg Med 2014; 21: 118–24.
11. Tamhankar MA, Volpe NJ. Management of acute cranial nerve 3, 4, and 6 palsies: role of neuroimaging. Curr Opin Ophthalmol. 2015; 26: 464-8.
12. Richner M, Ferreira N, Dudele A, Jensen TS, Vaegter CB, Gonçalves NP.
Functional and Structural Changes of the Blood-Nerve-Barrier in Diabetic Neuropathy. Front Neurosci. 2019; 12(1038): 1-9.
13. Galtrey CM, Schon F, Nitkunan A. Microvascular Non-Arteritic Ocular Motor Nerve Palsies—What We Know and How Should We Treat? Neuro-Ophthalmology. 2015; 39(1): 1–11.
14. Morisaki S, Nishi M, Fujiwara H, Oda R, Kawata M, dan Kubo T.
Endogenous Glucocorticoids Improve Mielination via Schwann Cells After Peripheral Nerve Injury: An In Vivo Study Using a Crush Injury Model. Glia.
2010; 58: 954–63.
15. Mekaj A dan Mekaj Y. The Role of Pharmacological Agents in Nerve Regeneration after Peripheral Nerve Repair. Dalam: Mauricio AC, editor.
Peripheral Nerve Regeneration: From Surgery to New Therapeutic Approaches Including Biomaterials and Cell-Based Therapies Development.
London: IntechOpen; 2017. hlm. 147-74.
16. Li Q, Li T, Cao XC, Luo DQ, Lian KJ. Methylprednisolone microsphere sustained‐release membrane inhibits scar formation at the site of peripheral nerve lesion. Neural Regeneration Research. 2016; 11: 835‐41.
17. Tezcan AH. Peripheral Nerve Injury and Current Treatment Strategies.
Dalam: Mauricio AC, editor. Peripheral Nerve Regeneration: From Surgery to New Therapeutic Approaches Including Biomaterials and Cell-Based Therapies Development. London: IntechOpen; 2017. hlm. 3-31.
18. Liu Q, Wang X, Yi S. Pathophysiological Changes of Physical Barriers of Peripheral Nerves After Injury. Front Neurosci. 2018; 12: 597.
19. Menorca RMG, Fussell TS, Elfar JC.Peripheral Nerve Trauma: Mechanisms of Injury and Recovery. Hand Clin. 2013; 29(3): 317–30.
20. Jessen KR, Mirsky R. The Success and Failure of the Schwann Cell Response to Nerve Injury. Front Cell Neurosci. 2019; 13(33): 1-14.
21. Liu B, Xin W, Tan JR, Zhu RP, Li T, Wang D, et al. Mielin sheath structure and regeneration in peripheral nerve injury repair. Proc Natl Acad Sci USA.
2019; 116(44): 22347-52.
22. Kanda T. Biology of the blood–nerve barrier and its alteration in immune mediated neuropathies. J Neurol Neurosurg Psychiatry 2013;84: 208–212.
23. Weerasuriya A, Mizisin AP. The Blood-Nerve Barrier: Structure and Functional Significance. Dalam: Nag S, editor. The Blood-Brain and Other Neural Barriers: Reviews and Protocols. Canada: Springer. 2011. hlm. 149-73.
24. Mizisin AP, Weerasuriya A. Homeostatic regulation of the endoneurial microenvironment during development, aging and in response to trauma, disease and toxic insult. Acta Neuropathol. 2011; 121: 291–312.
25. Alvites R, Caseiro AR, Pedrosa SS, Branquinho MV, Geuna S, Varejao ASP, et al. Peripheral Nerve Injury and Axonotmesis: State of The Art and Recent Advances. Cogent Medicine. 2018; 5: 1-45.
26. Li R, Li DH, Zhang HY, Wang J, Li XK, Xiao J. Growth factors-based therapeutic strategies and their underlying signaling mechanism for peripheral nerve regeneration. Acta Pharmacol Sin. 2020. 0; 1-12.
27. Brazis PW. Isolated Palsies of Cranial Nerves III, IV, and VI. Semin Neurol.
2009; 29: 14–28.
28. Jung JS, Kim DH. Risk Factors and Prognosis of Isolated Ischemic Third, Fourth, or Sixth Cranial Nerve Palsies in the Korean Population. J Neuro-Ophthalmol. 2015; 35: 37-40.
29. Dhume KU, Paul KE. Incidence of pupillary involvement, course of anisocoria and ophthalmoplegia in diabetic oculomotor nerve palsy. Indian J Ophthalmol 2013; 61: 13–7.
30. Murchison AP, Gilbert ME, Savino PJ. Neuroimaging and acute ocular motor mononeuropathies: a prospective study. Arch Ophthalmol. 2011; 129: 301-5.
31. Goncalves NP, Voegter CB, Andersen H, Ostergaard L, Calcutt NA, Jensen TS. Schwann cell interactions with axons and microvessels in diabetic neuropathy. Nat Rev Neurol. 2017. 13(3): 135-47.
32. Lutz AB dan Barres BA. Contrasting the Glial Response to Axon Injury in the Central and Peripheral Nervous Systems. Dev Cell. 2014. 28(1): 7-17.
33. Huebner EA, Strittmatter SM. Axon Regeneration in the Peripheral and Central Nervous Systems. Results Probl Cell Differ. 2009; 48: 339-51.
34. Michinaga S, Koyama Y. Pathogenesis of Brain Edema and Investigation into Anti-Edema Drugs. Int J Mol Sci. 2015; 16(5): 9949-75.
35. Lim TKY, Shi XQ, Johnson JM, Rone MB, Antel JP, David S, et al.
Peripheral Nerve Injury Induces Persistent Vascular Dysfunction and Endoneurial Hypoxia, Contributing to the Genesis of Neuropathic Pain. J Neurosci. 2015; 35(8): 3346-59.
36. Nishimoto S, Tanaka H, Okamoto M, Okada K, Murase T, Yoshikawa H.
Methylcobalamin promotes the differentiation of Schwann cells and remielination in lysophosphatidylcholine-induced demielination of the rat sciatic nerve. Front Cell Neurosci. 2015; 9(298): 1-13.
37. Jasielski P, Piedel F, Piwek M, Rocka A, Petit V, Rejdak K. Application of Citicoline in Neurological Disorders: A Systematic Review. Nutrients. 2020;
12(10): 3113.
38. Ozay R, Bekar A, Kocaeli H, Karl N, Filiz G, Ulus IH. Citicoline Improves Functional Recovery, Promotes Nerve Regeneration, and Reduces
Postoperative Scarring After Peripheral Nerve Surgery in Rats. Surgical Neurology. 2007; 68: 615-22.
39. Madalena KM, Lerch JK. The effect of glucocorticoid and glucocorticoid receptor interactions on brain, spinal cord, and glial cell plasticity. Neural Plast. 2017; 11(1): 37-41.
40. Yang J, Xu ZG, Rong R, Lü ZP, Sun YH, Zhao Y, et al. Effect of methylprednisolone on neurological behavior and the BDNF and NMDA receptor expression after traumatic spinal cord injury in rats. Sichuan da xue xue bao. 2012; 43(2):245-9.
41. Sun H, Yang T, Li Q, Zhu Z, Wang L, Bai G, et al. Dexamethasone and vitamin B(12) synergistically promote peripheral nerve regeneration in rats by upregulating the expression of brain-derived neurotrophic factor. Arch Med Sci. 2012; 9: 8(5): 924-30.
42. Desarnaud F, Bidichandani S, Patel PI, Baulieu EE, Schumacher M.
Glucocorticosteroids stimulate the activity of the promoters of peripheral myelin protein-22 and protein zero genes in Schwann cells. Brain Research.
2000; 865(1):12-6.
43. Saxena R, Singh D, Sharma M, James M. Steroids versus No Steroids in Nonarteritic Anterior Ischemic Optic Neuropathy. Ophthalmology. 2018;
125(10): 1623-7.
44. Lee AG, Biousse V. Should Steroids Be Offered to Patients with Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)? J Neuroophthalmol. 2010;
30(2): 193-8.
45. Chen J, Zhu J, Chen L, Hu C, Du Y. Steroids in The Treatment of Nonarteritic Anterior Ischemic Optic Neuropathy A PRISMA-compliant Meta-Analysis. Medicine. 2019; 98: 46.
46. Hayreh SS, Zimmerman MB. Non-arteritic anterior ischemic optic neuropathy: role of systemic corticosteroid therapy. Graefes Arch Clin Exp Ophthalmol. 2008; 246: 1029-46.
47. Bailie GR, Jhonson CA, Mason NA. Med facts: Pocket guide of drug interaction. Edisi ke-2. Nephrology Pharmacy Associates. 2004: 40-1.
48. Brophy KM, Scarlett-Ferguson H, Webber KS, Abraham AC, Lammon SB.
Clinical drug therapy for Canadian practice. Chapter 23 Corticosteroids.
Lippincott Williams and Wilkins. 2010: 370-1.
LAMPIRAN 1 PERSETUJUAN ETIK
72
LAMPIRAN 2
DAFTAR RIWAYAT HIDUP
Nama : Ludwig Melino Tjokrovonco,dr.
Tempat/ Tanggal lahir : Bandung, 11 Maret 1990
Alamat : Jl. Terusan Babakan Jeruk IV/44 Bandung.
Nama Orang Tua : Hasso Tjokrovonco, Dipl Ing.
Meliawati Kurnia Witrika
Nama Istri : Evelyn Irawan, dr.
Nama Anak : Ethan Lewis Tjokrovonco
Pendidikan Formal
1. TK Santo Aloysius I Sultan Agung (1994-1996) 2. SD Santo Aloysius Trunojoyo (1996-2002) 3. SMP Santo Aloysius I Sultan Agung (2002-2005) 4. SMA Santo Aloysius I Sultan Agung (2005-2008)
5. Program Studi Sarjana Kedokteran, Fakultas Kedokteran Universitas Kristen Maranatha Bandung (2008-2012)
6. Program Studi Profesi Dokter, Fakultas Kedokteran Universitas Kristen Maranatha Bandung (2012-2013)
7. Program Pendidikan Dokter Spesialis I Ilmu Kesehatan Mata Fakultas Kedokteran Universitas Padjadjaran/RS Mata Cicendo Bandung (2017-sekarang)
Riwayat Pekerjaan
1. Dokter Internship Tanjung Balai Karimun, Kepulauan Riau (2014-2015) 2. Dokter PTT di Puskesmas Jawakisa, Kabupaten Nagekeo, NTT (2015-2016)
73
Penelitian/ Publikasi
1. Efektivitas dan Keamanan Penggunaan Micropulse Transscleral Cyclophotocoagulation Pada Pasien Glaukoma Refrakter (2019)
2. Lensa Intraokulae Piggyback Sekunder Sebagai Tatalaksana Refractive Surprise.
Ophthalmologica Indonesiana. 2021
Presentasi Ilmiah
1. Clinical Outcomes of Various Micropulse Transscleral Cyclophotocoagulation Energy Settings for Very High Intraocular Pressure Refractory Glaucoma, Free Paper Presentation, Perdami Virtual Scientific Meeting (2020)
2. Orbital Apex Syndrome with Encephalitis as A Rare Complication of Herpes Zoster Ophthalmicus: A Case Report, Poster Presentation, 36th Asia-Pacific Academy of Ophthalmology Congress Virtual (2021)
Seminar/Kongres/Pertemuan Ilmiah Nasional/Internasional
2016 Peserta PERDAMI 14th National Congress & 41st Annual Scientific Meeting, Jakarta
2018 Peserta 6th INOIIS Scientific Meeting in Conjunction with INARVOS, Palembang
2019 Peserta 1st Cicendo International Ophthalmology Meeting, Bandung 2019 Peserta 5th INASCRS Biennial Meeting, Jakarta
2020 Peserta Perdami Visual Scientific Meeting, Jakarta
2021 Peserta The 7th Asia Cornea Society Biennial Scientific Meeting (ACS 2020), Osaka
2021 Peserta The 36th Asia-Pacific Academy of Ophthalmology Congress Virtual (APAO)
Penghargaan
1. Lulusan terbaik Program Studi Sarjana Kedokteran Umum Universitas Kristen Maranatha (2012)
2. Lulusan terbaik Program Studi Profesi Dokter Universitas Kristen Maranatha (2013)
3. 7th Winner of Ophthalmology Resident Free Paper Competition – Perdami Virtual Scientific Meeting (2020)
LAMPIRAN 3
PERHITUNGAN STATISTIK
Crosstabs
Case Processing Summary Cases
Valid Missing Total
N Percent N Percent N Percent
Jenis Kelamin * Tatalaksana 73 100.0% 0 0.0% 73 100.0%
Hipertensi * Tatalaksana 73 100.0% 0 0.0% 73 100.0%
Diabetes Mellitus * Tatalaksana 73 100.0% 0 0.0% 73 100.0%
Dislipidemia * Tatalaksana 73 100.0% 0 0.0% 73 100.0%
Stroke * Tatalaksana 73 100.0% 0 0.0% 73 100.0%
Penyakit Jantung Koroner * Tatalaksana
73 100.0% 0 0.0% 73 100.0%
Merokok * Tatalaksana 73 100.0% 0 0.0% 73 100.0%
Jumlah Faktor Resiko * Tatalaksana 73 100.0% 0 0.0% 73 100.0%
Nervus okular motor yang terlibat * Tatalaksana
73 100.0% 0 0.0% 73 100.0%
Tingkat Keparahan * Tatalaksana 73 100.0% 0 0.0% 73 100.0%
Jenis Kelamin * Tatalaksana
Crosstab
Tatalaksana Total
Kortikosteroid Tanpa Kortikosteroid
Jenis Kelamin
Laki-laki
Count 19 13 32
Expected Count 15.3 16.7 32.0
% within Tatalaksana 54.3% 34.2% 43.8%
Perempuan
Count 16 25 41
Expected Count 19.7 21.3 41.0
% within Tatalaksana 45.7% 65.8% 56.2%
Total
Count 35 38 73
Expected Count 35.0 38.0 73.0
% within Tatalaksana 100.0% 100.0% 100.0%
76
Chi-Square Tests
Value Df Asymp. Sig.
(2-sided)
Exact Sig.
(2-sided)
Exact Sig. (1-sided)
Pearson Chi-Square 2.982a 1 .084
Continuity Correctionb 2.223 1 .136
Likelihood Ratio 3.000 1 .083
Fisher's Exact Test .102 .068
Linear-by-Linear Association 2.942 1 .086
N of Valid Cases 73
a. 0 cells (0.0%) have expected count less than 5. The minimum expected count is 15.34.
b. Computed only for a 2x2 table
Hipertensi * Tatalaksana
Crosstab
Tatalaksana Total
Kortikosteroid Tanpa Kortikosteroid
Hipertensi Ya
Count 21 22 43
Expected Count 20.6 22.4 43.0
% within Tatalaksana 60.0% 57.9% 58.9%
Tidak
Count 14 16 30
Expected Count 14.4 15.6 30.0
% within Tatalaksana 40.0% 42.1% 41.1%
Total
Count 35 38 73
Expected Count 35.0 38.0 73.0
% within Tatalaksana 100.0% 100.0% 100.0%
Chi-Square Tests
Value df Asymp. Sig.
(2-sided)
Exact Sig.
(2-sided)
Exact Sig.
(1-sided)
Pearson Chi-Square .033a 1 .855
Continuity Correctionb .000 1 1.000
Likelihood Ratio .033 1 .855
Fisher's Exact Test 1.000 .522
Linear-by-Linear Association .033 1 .856
N of Valid Cases 73
a. 0 cells (0.0%) have expected count less than 5. The minimum expected count is 14.38.
b. Computed only for a 2x2 table
Diabetes Mellitus * Tatalaksana
Crosstab
Tatalaksana Total
Kortikosteroid Tanpa Kortikosteroid
Diabetes Mellitus Ya
Count 7 13 20
Expected Count 9.6 10.4 20.0
% within Tatalaksana 20.0% 34.2% 27.4%
Tidak
Count 28 25 53
Expected Count 25.4 27.6 53.0
% within Tatalaksana 80.0% 65.8% 72.6%
Total
Count 35 38 73
Expected Count 35.0 38.0 73.0
% within Tatalaksana 100.0% 100.0% 100.0%
Chi-Square Tests
Value df Asymp. Sig.
(2-sided)
Exact Sig.
(2-sided)
Exact Sig.
(1-sided)
Pearson Chi-Square 1.850a 1 .174
Continuity Correctionb 1.204 1 .272
Likelihood Ratio 1.875 1 .171
Fisher's Exact Test .199 .136
Linear-by-Linear Association 1.824 1 .177
N of Valid Cases 73
a. 0 cells (0.0%) have expected count less than 5. The minimum expected count is 9.59.
b. Computed only for a 2x2 table
Dislipidemia * Tatalaksana
Crosstab
Tatalaksana Total
Kortikosteroid Tanpa Kortikosteroid
Dislipidemia Ya
Count 29 29 58
Expected Count 27.8 30.2 58.0
% within Tatalaksana 82.9% 76.3% 79.5%
Tidak
Count 6 9 15
Expected Count 7.2 7.8 15.0
% within Tatalaksana 17.1% 23.7% 20.5%
Total
Count 35 38 73
Expected Count 35.0 38.0 73.0
% within Tatalaksana 100.0% 100.0% 100.0%
Chi-Square Tests Value df Asymp. Sig.
(2-sided)
Exact Sig.
(2-sided)
Exact Sig.
(1-sided)
Pearson Chi-Square .478a 1 .490
Continuity Correctionb .161 1 .688
Likelihood Ratio .481 1 .488
Fisher's Exact Test .570 .345
Linear-by-Linear Association
.471 1 .493
N of Valid Cases 73
a. 0 cells (0.0%) have expected count less than 5. The minimum expected count is 7.19.
b. Computed only for a 2x2 table
Stroke * Tatalaksana
Crosstab
Tatalaksana Total
Kortikosteroid Tanpa Kortikosteroid
Stroke Ya
Count 1 2 3
Expected Count 1.4 1.6 3.0
% within Tatalaksana 2.9% 5.3% 4.1%
Tidak
Count 34 36 70
Expected Count 33.6 36.4 70.0
% within Tatalaksana 97.1% 94.7% 95.9%
Total
Count 35 38 73
Expected Count 35.0 38.0 73.0
% within Tatalaksana 100.0% 100.0% 100.0%
Chi-Square Tests
Value df Asymp. Sig.
(2-sided)
Exact Sig.
(2-sided)
Exact Sig.
(1-sided)
Pearson Chi-Square .268a 1 .605
Continuity Correctionb .000 1 1.000
Likelihood Ratio .274 1 .601
Fisher's Exact Test 1.000 .531
Linear-by-Linear Association
.264 1 .607
N of Valid Cases 73
a. 2 cells (50.0%) have expected count less than 5. The minimum expected count is 1.44.
b. Computed only for a 2x2 table
Penyakit Jantung Koroner * Tatalaksana
Crosstab
Tatalaksana Total
Kortikosteroid Tanpa Kortikosteroid
Penyakit Jantung Koroner
Ya
Count 1 0 1
Expected Count .5 .5 1.0
% within Tatalaksana 2.9% 0.0% 1.4%
Tidak
Count 34 38 72
Expected Count 34.5 37.5 72.0
% within Tatalaksana 97.1% 100.0% 98.6%
Total
Count 35 38 73
Expected Count 35.0 38.0 73.0
% within Tatalaksana 100.0% 100.0% 100.0%
Chi-Square Tests Value df Asymp. Sig.
(2-sided)
Exact Sig.
(2-sided)
Exact Sig.
(1-sided)
Pearson Chi-Square 1.101a 1 .294
Continuity Correctionb .002 1 .967
Likelihood Ratio 1.485 1 .223
Fisher's Exact Test .479 .479
Linear-by-Linear Association
1.086 1 .297
N of Valid Cases 73
a. 2 cells (50.0%) have expected count less than 5. The minimum expected count is .48.
b. Computed only for a 2x2 table
Merokok * Tatalaksana
Crosstab
Tatalaksana Total
Kortikosteroid Tanpa Kortikosteroid
Merokok Ya
Count 8 5 13
Expected Count 6.2 6.8 13.0
% within Tatalaksana 22.9% 13.2% 17.8%
Tidak
Count 27 33 60
Expected Count 28.8 31.2 60.0
% within Tatalaksana 77.1% 86.8% 82.2%
Total
Count 35 38 73
Expected Count 35.0 38.0 73.0
% within Tatalaksana 100.0% 100.0% 100.0%
Chi-Square Tests Value df Asymp. Sig.
(2-sided)
Exact Sig.
(2-sided)
Exact Sig.
(1-sided)
Pearson Chi-Square 1.171a 1 .279
Continuity Correctionb .602 1 .438
Likelihood Ratio 1.176 1 .278
Fisher's Exact Test .363 .219
Linear-by-Linear Association
1.155 1 .283
N of Valid Cases 73
a. 0 cells (0.0%) have expected count less than 5. The minimum expected count is 6.23.
b. Computed only for a 2x2 table
Jumlah Faktor Resiko * Tatalaksana
Crosstab
Tatalaksana Total
Kortikosteroid Tanpa Kortikosteroid
Jumlah Faktor Resiko
1 Faktor resiko
Count 8 11 19
Expected Count 9.1 9.9 19.0
% within Tatalaksana 22.9% 28.9% 26.0%
2 Faktor Resiko
Count 22 21 43
Expected Count 20.6 22.4 43.0
% within Tatalaksana 62.9% 55.3% 58.9%
3 Faktor resiko
Count 5 6 11
Expected Count 5.3 5.7 11.0
% within Tatalaksana 14.3% 15.8% 15.1%
Total
Count 35 38 73
Expected Count 35.0 38.0 73.0
% within Tatalaksana 100.0% 100.0% 100.0%
Chi-Square Tests
Value Df Asymp. Sig.
(2-sided)
Pearson Chi-Square .465a 2 .792
Likelihood Ratio .467 2 .792
Linear-by-Linear Association .095 1 .758
N of Valid Cases 73
a. 0 cells (0.0%) have expected count less than 5. The minimum expected count is 5.27.
Nervus okular motor yang terlibat * Tatalaksana
Crosstab
Tatalaksana Total
Kortikosteroid Tanpa Kortikosteroid
Nervus okular motor yang terlibat
Paralisis nervus okulomotorius Komplit
Count 2 3 5
Expected Count 2.4 2.6 5.0
% within Tatalaksana 5.7% 7.9% 6.8%
Paralisis nervus okulomotorius Inomplit
Count 10 14 24
Expected Count 11.5 12.5 24.0
% within Tatalaksana 28.6% 36.8% 32.9%
Paralisis nervus troklearis
Count 7 6 13
Expected Count 6.2 6.8 13.0
% within Tatalaksana 20.0% 15.8% 17.8%
Paralisis nervus abdusen
Count 16 15 31
Expected Count 14.9 16.1 31.0
% within Tatalaksana 45.7% 39.5% 42.5%
Total
Count 35 38 73
Expected Count 35.0 38.0 73.0
% within Tatalaksana 100.0% 100.0% 100.0%
Chi-Square Tests
Value Df Asymp. Sig.
(2-sided)
Pearson Chi-Square .854a 3 .837
Likelihood Ratio .857 3 .836
Linear-by-Linear Association .624 1 .430
N of Valid Cases 73
a. 2 cells (25.0%) have expected count less than 5. The minimum expected count is 2.40.
Tingkat Keparahan * Tatalaksana
Crosstab
Tatalaksana Total
Kortikosteroid Tanpa Kortikosteroid
Tingkat Keparahan
Sangat Ringan
Count 15 16 31
Expected Count 14.9 16.1 31.0
% within Tatalaksana 42.9% 42.1% 42.5%
Ringan
Count 7 8 15
Expected Count 7.2 7.8 15.0
% within Tatalaksana 20.0% 21.1% 20.5%
Sedang
Count 5 5 10
Expected Count 4.8 5.2 10.0
% within Tatalaksana 14.3% 13.2% 13.7%
Berat
Count 8 9 17
Expected Count 8.2 8.8 17.0
% within Tatalaksana 22.9% 23.7% 23.3%
Total
Count 35 38 73
Expected Count 35.0 38.0 73.0
% within Tatalaksana 100.0% 100.0% 100.0%
Chi-Square Tests
Value df Asymp. Sig.
(2-sided)
Pearson Chi-Square .035a 3 .998
Likelihood Ratio .035 3 .998
Linear-by-Linear Association .002 1 .964
N of Valid Cases 73
a. 1 cells (12.5%) have expected count less than 5. The minimum expected count is 4.79.
NPar Tests
Two-Sample Kolmogorov-Smirnov Test
Frequencies
Tatalaksana N
Nervus okular motor yang terlibat
Kortikosteroid 35
Tanpa Kortikosteroid 38
Total 73
Test Statisticsa
Nervus okular motor yang
terlibat
Most Extreme Differences
Absolute .105
Positive .105
Negative .000
Kolmogorov-Smirnov Z .446
Asymp. Sig. (2-tailed) .989
a. Grouping Variable: Tatalaksana
Crosstabs
Case Processing Summary Cases
Valid Missing Total
N Percent N Percent N Percent
MRI * Tatalaksana 33 100.0% 0 0.0% 33 100.0%
CT * Tatalaksana 33 100.0% 0 0.0% 33 100.0%
MRA * Tatalaksana 33 100.0% 0 0.0% 33 100.0%
CTA * Tatalaksana 33 100.0% 0 0.0% 33 100.0%
MRI * Tatalaksana
Crosstab
Tatalaksana Total
Kortikosteroid Tanpa Kortikosteroid
MRI Ya
Count 5 13 18
Expected Count 4.9 13.1 18.0
% within Tatalaksana 55.6% 54.2% 54.5%
Tidak
Count 4 11 15
Expected Count 4.1 10.9 15.0
% within Tatalaksana 44.4% 45.8% 45.5%
Total
Count 9 24 33
Expected Count 9.0 24.0 33.0
% within Tatalaksana 100.0% 100.0% 100.0%
Chi-Square Tests Value df Asymp. Sig.
(2-sided)
Exact Sig.
(2-sided)
Exact Sig.
(1-sided)
Pearson Chi-Square .005a 1 .943
Continuity Correctionb .000 1 1.000
Likelihood Ratio .005 1 .943
Fisher's Exact Test 1.000 .627
Linear-by-Linear Association
.005 1 .944
N of Valid Cases 33
a. 2 cells (50.0%) have expected count less than 5. The minimum expected count is 4.09.
b. Computed only for a 2x2 table
CT * Tatalaksana
Crosstab
Tatalaksana Total
Kortikosteroid Tanpa Kortikosteroid
CT
Ya
Count 7 15 22
Expected Count 6.0 16.0 22.0
% within Tatalaksana 77.8% 62.5% 66.7%
Tidak
Count 2 9 11
Expected Count 3.0 8.0 11.0
% within Tatalaksana 22.2% 37.5% 33.3%
Total
Count 9 24 33
Expected Count 9.0 24.0 33.0
% within Tatalaksana 100.0% 100.0% 100.0%
Chi-Square Tests
Value Df Asymp. Sig.
(2-sided)
Exact Sig.
(2-sided)
Exact Sig.
(1-sided)
Pearson Chi-Square .688a 1 .407
Continuity Correctionb .172 1 .678
Likelihood Ratio .720 1 .396
Fisher's Exact Test .681 .347
Linear-by-Linear Association .667 1 .414
N of Valid Cases 33
a. 1 cells (25.0%) have expected count less than 5. The minimum expected count is 3.00.
b. Computed only for a 2x2 table
MRA * Tatalaksana
Crosstab
Tatalaksana Total
Kortikosteroid Tanpa Kortikosteroid
MRA Ya
Count 0 1 1
Expected Count .3 .7 1.0
% within Tatalaksana 0.0% 4.2% 3.0%
Tidak
Count 9 23 32
Expected Count 8.7 23.3 32.0
% within Tatalaksana 100.0% 95.8% 97.0%
Total
Count 9 24 33
Expected Count 9.0 24.0 33.0
% within Tatalaksana 100.0% 100.0% 100.0%
Chi-Square Tests
Value df Asymp. Sig.
(2-sided)
Exact Sig.
(2-sided)
Exact Sig.
(1-sided)
Pearson Chi-Square .387a 1 .534
Continuity Correctionb .000 1 1.000
Likelihood Ratio .649 1 .421
Fisher's Exact Test 1.000 .727
Linear-by-Linear Association .375 1 .540
N of Valid Cases 33
a. 2 cells (50.0%) have expected count less than 5. The minimum expected count is .27.
b. Computed only for a 2x2 table
CTA * Tatalaksana
Crosstab
Tatalaksana Total
Kortikosteroid Tanpa Kortikosteroid
CTA Tidak
Count 9 24 33
Expected Count 9.0 24.0 33.0
% within Tatalaksana 100.0% 100.0% 100.0%
Total
Count 9 24 33
Expected Count 9.0 24.0 33.0
% within Tatalaksana 100.0% 100.0% 100.0%
Chi-Square Tests Value
Pearson Chi-Square .a
N of Valid Cases 33
a. No statistics are computed because CTA is a constant.
Explore
Tatalaksana
Case Processing Summary
Tatalaksana Cases
Valid Missing Total
N Percent N Percent N Percent
Usia
Kortikosteroid 35 100.0% 0 0.0% 35 100.0%
Tanpa Kortikosteroid 38 100.0% 0 0.0% 38 100.0%
Onset (minggu)
Kortikosteroid 35 100.0% 0 0.0% 35 100.0%
Tanpa Kortikosteroid 38 100.0% 0 0.0% 38 100.0%
Descriptives
Tatalaksana Statistic Std. Error
Usia
Kortikosteroid
Mean 56.8571 1.19463
95% Confidence Interval for Mean
Lower Bound
54.4294
Upper Bound 59.2849
5% Trimmed Mean 56.3175
Median 53.0000
Variance 49.950
Std. Deviation 7.06750
Minimum 50.00
Maximum 76.00
Range 26.00
Interquartile Range 11.00
Skewness .913 .398
Kurtosis -.061 .778
Tanpa Kortikosteroid
Mean 58.2632 1.11289
95% Confidence Interval for Mean
Lower Bound
56.0082
Upper Bound 60.5181
5% Trimmed Mean 57.7807
Median 56.0000
Variance 47.064
Std. Deviation 6.86032
Minimum 50.00
Maximum 79.00
Range 29.00
Interquartile Range 11.00
Skewness .878 .383
Kurtosis .775 .750
Onset
(minggu) Kortikosteroid
Mean 2.1571 .23079
95% Confidence Interval for Mean
Lower Bound
1.6881
Upper Bound 2.6262
5% Trimmed Mean 2.1190
Median 1.0000
Variance 1.864
Std. Deviation 1.36539
Minimum 1.00
Maximum 4.00
Range 3.00
Interquartile Range 3.00
Skewness .513 .398
Kurtosis -1.665 .778
Tanpa Kortikosteroid
Mean 2.5658 .18874
95% Confidence Interval for Mean
Lower Bound
2.1834
Upper Bound 2.9482
5% Trimmed Mean 2.5731
Median 2.2500
Variance 1.354
Std. Deviation 1.16347
Minimum 1.00
Maximum 4.00
Range 3.00
Interquartile Range 2.50
Skewness .049 .383
Kurtosis -1.541 .750
Tests of Normality
Tatalaksana Kolmogorov-Smirnova Shapiro-Wilk
Statistic df Sig. Statistic df Sig.
Usia
Kortikosteroid .222 35 .000 .855 35 .000
Tanpa Kortikosteroid .156 38 .021 .925 38 .014
Onset (minggu)
Kortikosteroid .316 35 .000 .707 35 .000
Tanpa Kortikosteroid .207 38 .000 .851 38 .000
a. Lilliefors Significance Correction
Nonparametric Tests
Explore
Tatalaksana
Case Processing Summary
Tatalaksana Cases
Valid Missing Total
N Percent N Percent N Percent
Waktu Resolusi
Kortikosteroid 33 100.0% 0 0.0% 33 100.0%
Tanpa Kortikosteroid 27 100.0% 0 0.0% 27 100.0%
Descriptives
Tatalaksana Statistic Std. Error
Waktu Resolusi
Kortikosteroid
Mean 8.0000 1.12731
95% Confidence Interval for Mean
Lower Bound 5.7037 Upper Bound 10.2963
5% Trimmed Mean 7.5000
Median 4.0000
Variance 41.938
Std. Deviation 6.47592
Minimum 1.00
Maximum 24.00
Range 23.00
Interquartile Range 8.50
Skewness 1.180 .409
Kurtosis .729 .798
Tanpa Kortikosteroid
Mean 12.7778 1.45231
95% Confidence Interval for Mean
Lower Bound 9.7925 Upper Bound 15.7630
5% Trimmed Mean 12.7243
Median 12.0000
Variance 56.949
Std. Deviation 7.54644
Minimum 2.00
Maximum 24.00
Range 22.00
Interquartile Range 12.00
Skewness .413 .448
Kurtosis -1.224 .872
Tests of Normality
Tatalaksana Kolmogorov-Smirnova Shapiro-Wilk
Statistic df Sig. Statistic Df Sig.
Waktu Resolusi
Kortikosteroid .247 33 .000 .846 33 .000
Tanpa Kortikosteroid .208 27 .004 .877 27 .004
a. Lilliefors Significance Correction
Nonparametric Tests
Crosstabs
Case Processing Summary Cases
Valid Missing Total
N Percent N Percent N Percent
Tingkat Resolusi 3 bulan * Tatalaksana
73 100.0% 0 0.0% 73 100.0%
Tingkat Resolusi 6 bulan * Tatalaksana
73 100.0% 0 0.0% 73 100.0%
Tingkat Resolusi 3 bulan * Tatalaksana
Crosstab
Tatalaksana Total
Kortikosteroid Tanpa Kortikosteroid
Tingkat Resolusi 3 bulan
Komplit
Count 29 18 47
Expected Count 22.5 24.5 47.0
% within Tatalaksana 82.9% 47.4% 64.4%
Parsial
Count 6 10 16
Expected Count 7.7 8.3 16.0
% within Tatalaksana 17.1% 26.3% 21.9%
Tanpa Resolusi
Count 0 10 10
Expected Count 4.8 5.2 10.0
% within Tatalaksana 0.0% 26.3% 13.7%
Total
Count 35 38 73
Expected Count 35.0 38.0 73.0
% within Tatalaksana 100.0% 100.0% 100.0%
Chi-Square Tests
Value df Asymp. Sig.
(2-sided)
Pearson Chi-Square 13.474a 2 .001
Likelihood Ratio 17.349 2 .000
Linear-by-Linear Association 13.101 1 .000
N of Valid Cases 73
a. 1 cells (16.7%) have expected count less than 5. The minimum expected count is 4.79.
Tingkat Resolusi 6 bulan * Tatalaksana
Crosstab
Tatalaksana Total
Kortikosteroid Tanpa Kortikosteroid
Tingkat Resolusi 6 bulan
Komplit
Count 33 27 60
Expected Count 28.8 31.2 60.0
% within Tatalaksana 94.3% 71.1% 82.2%
Parsial
Count 2 5 7
Expected Count 3.4 3.6 7.0
% within Tatalaksana 5.7% 13.2% 9.6%
Tanpa Resolusi
Count 0 6 6
Expected Count 2.9 3.1 6.0
% within Tatalaksana 0.0% 15.8% 8.2%
Total
Count 35 38 73
Expected Count 35.0 38.0 73.0
% within Tatalaksana 100.0% 100.0% 100.0%
Chi-Square Tests
Value Df Asymp. Sig.
(2-sided)
Pearson Chi-Square 7.776a 2 .020
Likelihood Ratio 10.124 2 .006
Linear-by-Linear Association 7.667 1 .006
N of Valid Cases 73
a. 4 cells (66.7%) have expected count less than 5. The minimum expected count is 2.88.
NPar Tests
Two-Sample Kolmogorov-Smirnov Test
Frequencies
Tatalaksana N
Tingkat Resolusi 6 bulan
Kortikosteroid 35
Tanpa Kortikosteroid 38
Total 73
Test Statisticsa
Tingkat Resolusi 6 bulan
Most Extreme Differences
Absolute .232
Positive .000
Negative -.232
Kolmogorov-Smirnov Z .992
Asymp. Sig. (2-tailed) .279
a. Grouping Variable: Tatalaksana
99 I. KELOMPOK TANPA KORTIKOSTEROID
No. JK Usia Onset
(minggu)
Tingkat Keparahan
Tingkat Resolusi 3 bulan pertama
Total Tingkat Resolusi 6
bulan
Waktu Resolusi
(minggu)
Faktor Vaskulopati Jumlah Faktor Risiko
Paralisis Nervus yang Terlibat
Hasil Pemeriksaan Penunjang
1. L 61 4 Berat Parsial Parsial - HT,DM,dislipidemia 3 CN III inkomplit CT scan: infark serebri
2. L 63 2 Berat tanpa resolusi tanpa resolusi - Dislipidemia, rokok 2 CN III inkomplit CT scan-MRI: infark lakuner multipel 3. P 60 3 Sedang tanpa resolusi tanpa resolusi - HT, dislipidemia 2 CN III inkomplit MRI: infark lakuner multipel
4. L 64 2 Sedang Parsial Parsial - Dislipidemia 1 CN III komplit CT scan: normal
5. P 51 1.5 Berat Komplit Komplit 12 HT,DM,dislipidemia 3 CN III inkomplit -
6. P 54 3 Berat Komplit Komplit 4 HT,DM,dislipidemia 3 CN III inkomplit -
7. P 59 4 Ringan Komplit Komplit 4 HT, rokok 2 CN III inkomplit -
8. P 64 4 sangat ringan tanpa resolusi Komplit 16 DM, dislipidemia 2 CN III inkomplit MRI-MRA: normal
9. L 56 4 Ringan Parsial Komplit 24 Dislipidemia,rokok 2 CN III inkomplit CT scan: normal
10. P 70 3 Berat tanpa resolusi tanpa resolusi - HT, dislipidemia 2 CN III inkomplit CT scan: infark serebri
11. P 56 1 Ringan Komplit Komplit 10 HT, dislipidemia 2 CN III komplit -
12. L 65 2 Berat Parsial Komplit 20 HT, DM 2 CN III inkomplit MRI: infark corpus callosum
13. P 50 1 Sedang Komplit Komplit 8 DM, dislipidemia 2 CN III komplit -
14. P 52 4 sangat ringan tanpa resolusi Komplit 24 DM, dislipidemia 2 CN III inkomplit CT scan: normal
15. P 61 2 sangat ringan Komplit Komplit 5 HT,DM,dislipidemia 3 CN III komplit -
16. P 51 2 Sedang Komplit Komplit 12 HT, dislipidemia 2 CN III inkomplit MRI: normal
17. L 50 2 sangat ringan Komplit Komplit 2 DM 1 CN III inkomplit
18. P 60 1 Ringan Komplit Komplit 4 Dislipidemia 1 CN IV
19. L 55 1.5 sangat ringan Komplit Komplit 4 HT, dislipidemia 2 CN IV CT scan- MRI: normal
20. L 62 1 sangat ringan Komplit Komplit 8 HT, dislipidemia 2 CN IV
21. L 66 1 sangat ringan Komplit Komplit 12 Stroke, rokok 2 CN IV
99